Telomir Pharmaceuticals, Inc./$TELO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Ticker
$TELO
Sector
Primary listing
Employees
-
Headquarters
Website
TELO Metrics
BasicAdvanced
$43M
-
-$0.54
-
-
Price and volume
Market cap
$43M
52-week high
$5.40
52-week low
$1.12
Average daily volume
2.9M
Financial strength
Current ratio
2.381
Quick ratio
2.165
Total debt to equity
19.416
Interest coverage (TTM)
-11,606.13%
Profitability
Management effectiveness
Return on assets (TTM)
-686.94%
Return on equity (TTM)
-1,569.59%
Valuation
Price to book
84.34
Price to tangible book (TTM)
84.34
Price to free cash flow (TTM)
-12.575
Free cash flow yield (TTM)
-7.95%
Free cash flow per share (TTM)
-0.106
Growth
Earnings per share change (TTM)
-18.32%
TELO News
AllArticlesVideos
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Accesswire7 days ago
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
Accesswire3 weeks ago
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
Accesswire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telomir Pharmaceuticals, Inc. stock?
Telomir Pharmaceuticals, Inc. (TELO) has a market cap of $43M as of September 16, 2025.
What is the P/E ratio for Telomir Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Telomir Pharmaceuticals, Inc. (TELO) stock is 0 as of September 16, 2025.
Does Telomir Pharmaceuticals, Inc. stock pay dividends?
No, Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Telomir Pharmaceuticals, Inc. dividend payment date?
Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders.
What is the beta indicator for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. (TELO) does not currently have a Beta indicator.